MSN Pharma was given FDA approval for its Entresto (sacubitril and valsartan) generic on 24th July, prompting a lawsuit from Novartis claiming patent infringement and seeking a preliminary ...

Doses were titrated over 6 months (daily maximums, 160 mg and 10 mg, respectively), and agents from other drug classes were ... treatment previously. Valsartan's manufacturer sponsored the trial.

MSN Pharma was given FDA approval for its Entresto (sacubitril and valsartan) generic on 24th July, prompting a legal complaint from Novartis seeking to block its launch. In August, a Delaware ...

Case Name: In re Entresto, 125 F.4th 1090 (Fed. Cir. Jan. 10, 2025) (Circuit Judges Lourie, Prost, and Reyna presiding; Opinion by Lourie, C.J.) (Appeal from D. Del ...

For the duration of trial 1, 61.0% of patients received valsartan alone, whereas 39.0% received additional antihypertensive agents at some point during the study. In trial 2, 75.8% of patients ...

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual ...

Gov. Gavin Newsom has made California the first state to offer a generic version of the overdose-reversal drug Narcan for public purchase through a state-run storefront, while the state’s health ...

Get all latest & breaking news on Hetero Drugs. Watch videos, top stories and articles on Hetero Drugs at moneycontrol.com.

With an aim to make stakeholders aware of the not-of-standard-quality (NSQ) batches identified in the market, in its latest ...